Featured Research

from universities, journals, and other organizations

First Effective Drug For Sleep Disorder Identified

Date:
June 5, 2003
Source:
University Of Illinois At Chicago
Summary:
In a clinical trial conducted at the University of Illinois at Chicago, researchers have demonstrated the first promising drug treatment for a common and life-threatening sleep disorder called sleep apnea.

In a clinical trial conducted at the University of Illinois at Chicago, researchers have demonstrated the first promising drug treatment for a common and life-threatening sleep disorder called sleep apnea. The drug, an antidepressant called mirtazapine, significantly reduced the symptoms of sleep apnea. It cut in half the number of times breathing stopped or slowed during sleep and reduced the number of times sleep was disrupted by 28 percent. All 12 patients who participated in the study showed improvement.

"The drug provided the largest benefit and the most consistent improvement of any pharmaceutical therapy tested in controlled studies to date," said David Carley, professor of medicine, pharmacology and bioengineering and director of research at the UIC Center for Sleep and Ventilatory Disorders.

The results of the trial will be presented this week at the annual meeting of the Associated Professional Sleep Societies in Chicago by Carley and co-investigator Dr. Miodrag Radulovacki, professor of pharmacology and medicine at UIC.

"This has real clinical significance," said Radulovacki. "An estimated 15-20 million people in the United States suffer from sleep apnea, yet there is currently no cure and no fully effective long-term treatment for the disorder."

Apnea -- which means "without breath" -- is diagnosed when a person periodically stops breathing for 10 seconds or more or has episodes of reduced breathing during sleep. People suffering from sleep apnea may stop breathing hundreds of times a night, often for a minute or longer. The disorder is associated with increased risk of high blood pressure, heart attack, stroke and adult-onset diabetes. Behavioral problems and cognitive impairments can occur due to insufficient rest.

At present, sleep apnea is treated with mechanical devices, most often masks or nasal prongs, that maintain a continuous positive airway pressure. Such devices are uncomfortable, however, and difficult to use long-term.

The 12 patients in the UIC study were between the ages of 20 and 70. They received one of two dosages of mirtazapine or a placebo an hour before bedtime. They were monitored throughout the night in the UIC Center for Sleep and Ventilatory Disorders after each of three seven-day treatment periods.

The clinical trial at UIC followed years of laboratory tests of several classes of medications on a strain of rats that exhibit sleep apneas similar to the human disorder. Mirtazapine showed the most promise; other drugs either improved the condition only marginally or made it worse.

Mirtazapine blocks the activity of a chemical in the nervous system called serotonin that is involved in regulating mood, emotion, appetite and sleep.

The UIC study was funded by NV Organon, which markets mirtazapine as Remeron for the treatment of depression.

Mirtazapine has not been approved by the U.S. Food and Drug Administration for the treatment of sleep apnea. Its use in this trial was approved by a UIC institutional review board for experimental purposes only.


Story Source:

The above story is based on materials provided by University Of Illinois At Chicago. Note: Materials may be edited for content and length.


Cite This Page:

University Of Illinois At Chicago. "First Effective Drug For Sleep Disorder Identified." ScienceDaily. ScienceDaily, 5 June 2003. <www.sciencedaily.com/releases/2003/06/030605081837.htm>.
University Of Illinois At Chicago. (2003, June 5). First Effective Drug For Sleep Disorder Identified. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2003/06/030605081837.htm
University Of Illinois At Chicago. "First Effective Drug For Sleep Disorder Identified." ScienceDaily. www.sciencedaily.com/releases/2003/06/030605081837.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins